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Established facts: 
 Hypoparathyroidism associated with malabsorption can be particularly 
challenging to manage in children due to limited and often erratic 
intestinal absorption of calcium and vitamin D analogues. 
 Conventional treatment in these children is often associated with 
symptomatic hypocalcaemia and hypo/ hypercalcaemia-related hospital 
admissions.  
Novel insights: 
 Continuous subcutaneous recombinant parathyroid (rhPTH 1-34) hormone 
infusion results in the normalisation and stabilisation of serum calcium 
and phosphate and therefore is a promising and effective alternative 
treatment option for children with hypoparathyroidism associated with 
intestinal malabsorption. 
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Abstract: 38 
Background/ Aims:  Hypoparathyroidism associated with malabsorption can be 39 
particularly challenging to manage due to limited and erratic intestinal 40 
absorption of calcium and vitamin D analogues, resulting in episodes of hypo- or 41 
hypercalcaemia. We evaluated the role of continuous subcutaneous recombinant 42 
parathyroid (rhPTH 1-34) hormone infusion (CSPI) in children with 43 
hypoparathyroidism associated with intestinal malabsorption resistant to 44 
conventional therapy. 45 
Method: Four patients (8 - 13 years), with symptomatic hypocalcaemia resistant 46 
to conventional therapy were started on CSPI (follow up 3-8 years), in two 47 
paediatric endocrinology units in Europe. 48 
Results: Serum calcium normalised within 48 hours of commencing treatment in 49 
all 4 patients. An average rhPTH 1-34 dose of 0.4 µg/kg/day resulted in a 50 
substantial reduction in symptomatic hypocalcaemia and hypo/ hypercalcaemia-51 
related hospital admissions. An increased alkaline phosphatase activity was 52 
noted in the first six months on CSPI, indicating increase in bone turnover. In 2 53 
patients with elevated urinary calcium excretion pre CSPI, this normalised in the 54 
first year on treatment. No significant side effects were noticed in the short or 55 
long term, with patient-reported   preference of CSPI over conventional 56 
treatment.  57 
 4 
Conclusion: CSPI is a promising and effective treatment option for managing 58 
hypocalcaemia and hyperphosphatemia in children with hypoparathyroidism 59 
associated with intestinal malabsorption. 60 
 61 
 62 
1. Introduction: 63 
Hypoparathyroidism is a rare endocrine disorder characterized by low serum 64 
calcium with an inappropriately low or normal serum parathyroid hormone 65 
(PTH) level. [1] In children, it is commonly associated with either defects in 66 
genes involved in parathyroid gland development (TBX1/22q11.2 del, GCMB), 67 
function (calcium-sensing receptor CaSR, GNA11 and PTH), or auto-immune 68 
polyglandular syndrome type 1 (AIRE). [2, 3] 69 
Along with maintaining calcium and phosphate homeostasis through stimulation 70 
of osteoclastic bone resorption, PTH plays a vital role in calcium reabsorption 71 
and phosphate excretion in the renal tubules. PTH also facilitates conversion of 72 
25 hydroxy vitamin D (25OHD) to the active 1,25 dihydroxy vitamin D [1,25 73 
(OH)2D] which enhances intestinal calcium and phosphate absorption. [4] 74 
Unlike other hormone deficiency states, replacing the missing hormone in 75 
hypoparathyroidism is not routine practice. Instead, conventional therapy with 76 
oral calcium supplements and vitamin D analogues remains the mainstay of 77 
treatment. [5] The role of synthetic subcutaneous PTH injections in the 78 
treatment of hypoparathyroidism was first reported in adults in 1996 [6, 7] 79 
followed by children in 2008. [8] Since then, short [9] and long term studies [10] 80 
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have demonstrated the efficacy and safety of Continuous Subcutaneous 81 
Recombinant PTH1-34 Infusion (CSPI) in the management of hypocalcaemia in 82 
children with activating mutations in CaSR and with autoimmune 83 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).  84 
Managing hypocalcaemia with conventional therapy can be particularly 85 
challenging in children with hypoparathyroidism associated with intestinal 86 
malabsorption, where calcium and active vitamin D analogue absorption capacity 87 
is both limited and highly variable. Here we report the favourable effects of CSPI 88 
in four children with resistant hypocalcaemia secondary to hypoparathyroidism 89 
associated with malabsorption, managed in two tertiary paediatric 90 
endocrinology units in Europe, Birmingham Children’s Hospital, Birmingham, 91 
United Kingdom (patient 1) and Bicêtre Hospital, Paris, France (patient 2-4). 92 
2. Subjects and Methods: 93 
2.1. Case Reports: 94 
Patient 1 (P1): A 13-year-old boy, born to consanguineous South-Asian parents 95 
was diagnosed with congenital hypoparathyroidism in infancy. He was 96 
subsequently diagnosed with sensory neural hearing loss, developmental delay 97 
and cryptogenic liver disease requiring liver transplant at the age of 2 years. He 98 
developed persistent diarrhoea with hypoalbuminaemia, lymphopaenia, 99 
hypomagnesaemia and recurrent severe hypocalcaemia by the age of 3 years. 100 
Video capsule endoscopy confirmed extensive intestinal lymphangectasia, not 101 
amenable to surgery. Genetic analysis has not identified any significant 102 
abnormalities to date.  Despite high doses of alfacalcidol (200ng/kg), oral 103 
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calcium (300mg/kg/day) and magnesium supplements (15mg/kg/day) his 104 
serum calcium remained between 1.26 and 1.98 mmol/L. High doses of oral 105 
calcium supplements led to worsening diarrhoea. Multiple hospital admissions 106 
with hypocalcaemic seizures or symptomatic refractory hypocalcaemia requiring 107 
i.v. calcium infusions ensued. At the age of 13 years, he was commenced on CSPI 108 
delivered via a MedtronicTM pump and successfully weaned off alfacalcidol, 109 
magnesium and calcium supplements.  His serum calcium normalised and 110 
stabilised within 2 days of commencing s.c. rhPTH1-34 . His calcium homeostasis 111 
is carefully managed with a combination of 2 litres of medium chain triglyceride 112 
(MCT) feeds (calcium 35 mg/kg/day) via gastrostomy in conjunction with rhPTH 113 
1-34. He also receives regular oesophageal dilatation secondary to oesophageal 114 
strictures and recently underwent fundoplication due to severe 115 
gastroesophageal reflux. He has remained on CSPI for 3 years. 116 
Patient 2 (P2): This 13 year old boy born to non-consanguineous Caucasian 117 
parents, first presented at the age of 7 years with hypocalcaemic seizures. He 118 
was diagnosed with and treated for hypoparathyroidism with conventional 119 
therapy. He subsequently developed adrenal insufficiency aged 8.4 years, when a 120 
diagnosis of APECED was confirmed with a compound heterozygous mutation in 121 
AIRE gene inherited from parents. He also developed intermittent diarrhoea and 122 
hypercalciuria [urine Calcium: Creatinine ratio (Ca:Cr, in mmol/mmol) 1.3] on a 123 
modest dose of 40ng/kg of alphacalcidol. Despite a short trial on thiazide 124 
diuretics, hypercalciuria persisted with serum calcium of 1.9mmol/L. He 125 
subsequently developed renal cysts.  In view of intestinal malabsorption, poor 126 
growth and family history of polycystic kidney disease, he was commenced on 127 
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CSPI and pancreatic enzyme replacement (pancrelipase) therapy at the age of 9 128 
years, on which he has remained for 6 years. He is otherwise on a normal diet, 129 
his serum calcium stabilised and hypercalciuria resolved subsequently. 130 
Patient 3 (P3) and Patient 4 (P4) are 15 and 19 year old siblings, born to 131 
consanguineous Senegalese parents, with a diagnosis of APECED (homozygous 132 
AIRE gene mutation inherited from both parents) and glucose-6-phosphate 133 
dehydrogenase deficiency. P3 presented at 4 years of age with hypocalcaemic 134 
seizures (serum calcium 1.54 mmol/l).  Despite being started on high doses of 135 
alphacalcidol (125ng/kg/day) and oral calcium (85mg/kg/day), he had 136 
recurrent hospital admissions with episodes of hypocalcaemia alternating with 137 
hypercalcaemia and hypercalciuria. These problems persisted on a brief trial of 138 
twice daily subcutaneous injections (40µg) of rhPTH1-34. Intestinal 139 
malabsorption was confirmed due to elevated faecal calprotectin and low faecal 140 
elastase levels (Table 1). High doses of oral calcium resulted in worsening 141 
diarrhoea and the decision to commence CSPI was made. P4 presented at the age 142 
of 11 years in status epilepticus secondary to hypocalcaemia. Following 143 
normalisation of serum calcium with i.v calcium infusions, he was commenced on 144 
CSPI, for the purpose of consistency in the management of the two siblings. He 145 
subsequently developed diarrhoea and malabsorption was confirmed by 146 
elevated faecal calprotectin and low faecal elastase levels (Table 1). Primary 147 
adrenal insufficiency was diagnosed in P3 aged 8 years and P4 at the age of 12 148 
years. Both were commenced on treatment with hydrocortisone and 149 
fludrocortisone as well as on pancrelipase. Both siblings required intermittent 150 
intramuscular vitamin D injections, when adequate serum 25 OHD level was not 151 
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achieved on monthly oral vitamin D supplements (100,000 IU) alone. To our 152 
knowledge, P3 and 4 were the first reported children to be commenced on CSPI 153 
and P3 has remained on it for the longest duration of 8 years.[10] Here we focus 154 
on the initiation of their PTH therapy and highlight the challenges in managing 155 
resistant hypocalcemia in the context of malabsorption. 156 
P4 deceased at the age of 19 years, 6.5 years on CSPI treatment, due to acute 157 
adrenal insufficiency from septic shock secondary to a dental abscess. 158 
2.2. CSPI dosing and management: 159 
All patients were commenced on a continuous s.c. infusion of rhPTH1–34 160 
(teriparatide, European union trade name Forsteo, 20µg/80µl, Lilly France) 161 
delivered via a MedtronicTM pump.  The device was attached to the abdomen or 162 
lower back, and parents trained to fill the pump cartridge with teriparatide and 163 
change the cannula and infusion set every 72 hours. The pump was programmed 164 
to deliver a standard basal rate throughout the day and carers trained to either 165 
increase basal rate in increments of 10-20% during illness or self administer a 166 
bolus following discussion with the medical team. Patient 1 was commenced on 167 
an rhPTH1-34 dose of 0.16µg/kg/day, currently requiring a higher maintenance 168 
dose of 0.3 µg/kg/day.  Patient 2 was on an initial dose of 1µg/kg/day, gradually 169 
weaned down to 0.35µg/kg/day. P3 and P4, the very first patients to have 170 
commenced CSPI were started on a higher initial dose of 2.6µg/kg/day and 171 
weaned down to a maintenance dose of 0.5µg/kg/day in P3 (Table 2).[10] 172 
As this was not a clinical trial, no ethical approval was required. However as CSPI 173 
was commenced in these patients under exceptional circumstances, a 174 
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multidisciplinary team of experts approved this decision and individual patient 175 
funding requests were obtained from the respective national bodies. Consent 176 
was obtained from parents of all 4 children prior to commencing CSPI treatment 177 
and informed of the desired effects, potential side effects and uncertainties of 178 
long- term safety of treatment with CSPI in children.  179 
3. Results:  180 
Serum calcium normalized in all patients within 36-48 hrs of commencing CSPI. 181 
All patients were successfully weaned off alfacalcidol and only P3 remains on a 182 
reduced dose of oral calcium supplements (40 mg/kg/day). A similar effect was 183 
noted with serum phosphate (Figure 1).  P2 and P4 had elevated Ca:Cr at the 184 
start of  CSPI, which normalized in the first year of treatment (Figure 1). 185 
Episodes of hypercalcaemia and elevated urinary Ca:Cr in P3-4, 3-6 months into 186 
treatment guided rhPTH 1-34 dose reduction (Figure 1). 187 
P1, P3-4 had normal renal ultrasound scans with no evidence of nephrocalcinosis 188 
pre CSPI and this continues to remain the case on serial renal ultrasounds (1-3 189 
yearly) on treatment. Grade II nephrocalcinosis was detected in P2 in the first 190 
year of treatment but did not progress on subsequent ultrasound evaluations. 191 
Serum creatinine and estimated GFR remains normal for age in all 4 patients on 192 
CSPI. 193 
While P1 receives gastrostomy feeds, P2-3 are on a normal diet. Serum calcium 194 
throughout treatment remained correlated to 1,25(OH)2D activity in all patients 195 
(Figure 2). The 1,25(OH)2D concentrations were also elevated in all patients 196 
during therapy, which in the setting of malabsorption indicates that maximum 197 
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intestinal calcium absorption capacity is limited. As expected, serum calcium did 198 
not correlate with 25 OHD concentrations. 199 
All 4 patients had normal age- and sex- specific ALP activity at start of CSPI.  A 60 200 
-180 % increase from baseline in ALP activity was noted at 1 month following 201 
start of treatment, which returned to baseline by 6 months on CSPI (Figure 3).  202 
Lumbar Spine Bone mineral apparent density (LSBMAD) z score of P1 decreased 203 
from +3.0 pre CSPI to +2.8 and +2.1, 1 and 2 years on CSPI treatment, 204 
respectively. P2-4 only had LS BMAD measured 12-18 months on CSPI with z 205 
scores of -0.5, +1.5 and +1 respectively. There were no fractures reported in any 206 
of the patients on CSPI. 207 
A substantial reduction in hypocalcaemia-related hospital admissions were 208 
noted from approximately 5 admissions in the year prior to commencing CSPI, to 209 
2 calcium related admissions in the 1st year of treatment (Table 2). 210 
None of the patients have had to discontinue CSPI and reported preference of 211 
CSPI therapy over conventional treatment due to the perceived improvement in 212 
quality of life. P3 has remained on CSPI treatment for 8 years, with no clinically 213 
significant treatment-related adverse events observed.  214 
In our cohort, episodes of hypocalcaemia on CSPI were associated with 1) 215 
mechanical obstruction (catheter blockage or kinking) 2) insufficient vitamin D 216 
supplementation 3) systemic illness, which often requires temporary increase in 217 
basal rhPTH1-34 infusion rates to avoid hypocalcaemia or 4) insufficient oral 218 
calcium intake/ gastrostomy milk feeds and 5) pubertal growth spurt requiring 219 
temporary higher rhPTH1-34 doses to maintain normocalcemia. In most instances, 220 
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these episodes occurred secondary to a combination of the above mentioned 221 
factors. No cannula insertion site reactions or infections were recorded in any of 222 
the four patients. 223 
4. Discussion: 224 
Symptomatic hypocalcaemia associated with under treatment is a common 225 
occurrence with conventional treatment of hypoparathyroidism. Large doses of 226 
oral calcium supplements and alfacalcidol can result in worsening diarrhoea as 227 
observed in P1 and P3. In addition, erratic intestinal calcium absorption can lead 228 
to fluctuating serum calcium and hypercalciuria resulting in nephrocalcinosis. 229 
Here we report our experience demonstrating that this challenging subgroup of 230 
patients responds well to CSPI therapy with normalisation and stabilisation of 231 
serum calcium and phosphate resulting in reduced hospital admissions. The 232 
daily rhPTH1-34 maintenance dose varied (Table 2), likely related to the extent of 233 
malabsorption. CSPI is also the preferred mode of rhPTH1-34 delivery in these 234 
patients since stabilisation is difficult to achieve with twice daily subcutaneous 235 
injections. The fixed rhPTH1-34 doses available as injections are often several 236 
times higher than the total daily dose needed during CSPI in these children. 237 
From our experience, it is advisable to maintain 25OHD levels above 75 nmol/L 238 
in order to provide adequate substrate for PTH-induced conversion of 25OHD 239 
into active calcitriol (1,25(OH)2D). In the setting of malabsorption, it is often 240 
challenging to achieve adequate serum 25OHD by oral supplementation alone. 241 
Therefore, regular intramuscular vitamin D administration should be considered 242 
earlier on in the management of these patients as required in P3-4.  243 
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A significant increase in alkaline phosphatase activity was noted within the first 244 
month of starting CSPI in our patient cohort, in keeping with the increased bone 245 
turnover associated with rhPTH1-34 treatment in hypoparathyroidism . This 246 
however returned to pre-treatment levels within 6 months of commencing CSPI.  247 
We recognise the lack of consistent 24-hour urine calcium assessments in our 248 
cohort, as well as the challenges in measuring fasting serum calcium due to 249 
overnight feed requirement in P1. 250 
All four patients reported preference of CSPI over conventional treatment due to 251 
the ease of use, fewer episodes of symptomatic hypocalcaemia, and substantial 252 
reduction in hospitalisation perceived as an improvement in quality of life. 253 
Future studies will have to carefully assess quality of life, alongside other 254 
functional outcomes and long-term safety monitoring. 255 
Use of conventional treatment remains the mainstay in the treatment of 256 
hypoparathyroidism in children, due to the difficulty in dosing with recombinant 257 
parathyroid hormone and the boxed warning regarding the risk of osteosarcoma 258 
noted in rat toxicology studies [11, 12] but in no other animal models [13, 14]. It 259 
is essential to inform parents/ carers of the possible risks of CSPI treatment. The 260 
safety and efficacy of using rhPTH1-84 as an alternative treatment option needs to 261 
be further explored. [15, 16] 262 
In the absence of other new treatment options on the horizon in children, we 263 
propose CSPI as a promising and effective treatment method for children with 264 
hypoparathyroidism associated with intestinal malabsorption. However, we 265 
recommend careful monitoring of serum calcium daily for the first week, thrice 266 
weekly until serum calcium stabilizes in the normal range, later fortnightly, 267 
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monthly and 3 monthly or as clinically indicated. To avoid overtreatment urinary 268 
calcium excretion and renal ultrasound should be monitored periodically.  Until 269 
further evidence becomes available, we recommend bone density scans, total 270 
body less head and lumbar spine [17] every 2 years. CSPI should be managed in 271 
tertiary rare disease centres with the required expertise. Due to the substantially 272 
higher drug costs and uncertainties of long term adverse events, CSPI is 273 
currently restricted to patients unresponsive and/ or having serious 274 
complications of conventional therapy. 275 
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Table 1: Clinical and biochemical characteristics of the cohort 360 
M = male, APECED – Autoimmune polyendocrinopathy candidiasis ectodermal 361 
dystrophy 362 
 17 
Patient P1 P2 P3 P4 
Sex M M M M 
Age at 
diagnosis  
8 m 7 y 4 y 11 y 
Diagnosis Congenital          
hypoparathyroidis
m, sensory-neural 
deafness,  
intestinal 
lymphangectasia, 
cryptogenic liver 
disease 
APECED APECED APECED 
Gene mutation No abnormality 
detected 
Compound 
Heterozygous 
AIRE gene 
mutation 
(c.415 C>T 
exon 3 + 
c.967_979del 
exon 8) 
Homozygous 
AIRE gene 
mutation 
(c.958del 
exon 8) 
Homozygou
s AIRE gene 
mutation 
(c.958del 
exon 8) 
Coeliac screen negative negative negative negative 
Faecal 
calprotectin 
activity (μg/L)* 
 _  16 258 62 
Faecal elastase 
(μg/g)** 
> 500  408 82 40 
Other 
investigations 
for 
malabsorption 
Intestinal biopsy 
confirmed 
extensive 
lymphangectasia 
_  _  _ 
 363 
* Normal faecal calprotectin activity < 50 μg/L, **normal faecal elastase level > 364 
200 μg/g 365 
Table 2: Dosing, metabolic response and duration of Continuous 366 
Subcutaneous Recombinant PTH (1-34) Infusion (CSPI)  367 
Patient P1 P2 P3 P4 
 18 
Age at start of CSPI (years) 13 9 8 11 
Initiation dose (µg/kg/day) 0.16 1 2.6 2.6 
Maintenance dose 1yr on 
CSPI  (µg/kg/day)  
0.3 0.35 0.5 0.5 
Serum calcium normalised 
post CSPI initiation (days) 
2 2 2 2 
Calcium-related hospital 
admissions, 1 year pre CSPI 
8 3 10 1 
Calcium-related hospital 
admissions, 1 year on CSPI 
2 1 6 1 
Duration of CSPI therapy to 
date (years) 
3 6.5 8 6.5 
 368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
 378 
 379 
Figure Legends: 380 
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Figure 1: Normalisation and maintenance of serum calcium and phosphate 381 
[mean (SD)] and urinary calcium: creatinine ratio in the first two years on CSPI. 382 
Shaded area represents normal reference range. High urinary calcium excretion 383 
in P3 and P4, six months into treatment guided rhPTH 1-34 dose reduction.  384 
Figure 2: Serial measurements of serum calcium correlate significantly with 385 
rhPTH-driven serum 1,25(OH)2D concentrations (estimated R2 value 0.39, 95% 386 
confidence interval, 0.08-0.68 and two sided p value 0.001 using metacor 387 
package [18]). Normal range for 1,25(OH)2D (20-62.5pg/mL) [19].  A similar 388 
correlation with serum 25OHD concentrations was not evident in children on 389 
CSPI. 390 
Figure 3:  Effect of CSPI on serum alkaline phosphatase (ALP) activity. The 391 
transient rise in ALP activity in the first month demonstrates the restoration of 392 
bone turnover followed by normalisation of activity by 6 months on treatment. 393 
Note that the ALP assay used for P1 results in ALP levels approximately twice the 394 
ALP activity of assays used for P2-4. At start of therapy, ALP was within the 395 
normal range in all patients. 396 
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